Literature DB >> 30244066

Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment.

Joerg Albrecht1, Adewole S Adamson2, John S Barbieri3, Daniel D Bennett4, Elizabeth A Kiracofe5, A Shadi Kourosh6, Kieron S Leslie7, Joseph F Merola8, Josephine Nguyen9, Elaine Siegfried10, Nicole Strickland11, Suzanne Olbricht12, Maryam M Asgari13.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30244066     DOI： 10.1016/j.jaad.2018.09.016

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  3 in total

1.  Reply to "Innovation and off-label use, the French case and more" by Braillon and Lexchin.

Authors:  Jan Borysowski; Hans-Jörg Ehni; Andrzej Górski
Journal:  Br J Clin Pharmacol       Date:  2019-08-13       Impact factor: 4.335

2.  The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.

Authors:  Laura Karas; Christine Y Lu; Pankaj B Agrawal; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2019-05-16       Impact factor: 11.527

3.  The best pharmaceuticals for children-what can we do?

Authors:  Hao Li; Fang-Hong Shi; Shi-Ying Huang; Shun-Guo Zhang; Hui-Wen Chen
Journal:  Transl Pediatr       Date:  2020-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.